TAKING CANCER PERSONALLY
OUR PRECISION CANCER IMMUNOTHERAPIES ARE BASED ON
A SUPERIOR NEOANTIGEN PREDICTION PLATFORM
POWERED BY MACHINE LEARNING BASED ALGORITHMS
Next-generation sequencing has opened the door to precision cancer immunotherapies targeting mutations solely expressed by tumor cells.
Ancer™ prioritizes both CD8 and CD4 T cell neoepitopes and removes "Self-Like" inhibitory and cross reactive neoepitopes.
Ancer™ enables the rapid, in silico, discovery of highly immunogenic neoantigens for precision cancer immunotherapies.
Learn more about Ancer™ here.
EpiVax Oncology, Inc., is a precision cancer immunotherapy company, developing mutanome-directed, neo-epitope personalized immunotherapies.
EpiVax Oncology’s immunotherapies are customized and specifically designed for each patient’s tumors, leveraging advances in next generation sequencing and computational immunology.
Our superior neo-epitope selection process is based on Ancer™: an advanced in-silico neoantigen prediction platform powered by machine learning based algorithms, exclusively licensed to EpiVax Oncology by EpiVax.
Incorporated in 2017, privately held and based in New York City, EpiVax Oncology Inc. is a spin-out of EpiVax Inc. EpiVax Oncology leverages EpiVax’s world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.
We are addressing major unmet medical needs inadequately addressed by existing immuno-oncology approaches.
Find the latest updates related to EpiVax Oncology and Ancer here.
188 Valley Street
Providence, RI 02909